147353-95-5

Usage

Uses

Used in Cardiovascular Applications:
Carvedilol is employed as a beta-blocker for the management of high blood pressure, congestive heart failure, and left ventricular dysfunction post-heart attack. It functions by relaxing blood vessels and slowing the heart rate, which improves blood flow and reduces the strain on the heart. Its antioxidant and neuroprotective properties further contribute to its therapeutic benefits in cardiovascular conditions.
Used in Pharmaceutical Formulations:
Carvedilol is commonly available in tablet form and may be prescribed alone or in combination with other medications to effectively manage cardiovascular conditions. It is an essential component in various pharmaceutical formulations designed to address a range of cardiovascular issues.

Upstream product

• 179811-64-4 4-(aminomethyl)benzene-1,2-diol hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6212-33-5 2-(4-Chlorophenyl)glycine 

Downstream Products

• 1143534-14-8 2-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)ethyl methanesulfonate 
• 1143535-08-3 2-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)ethyl ethanethioate 
• 1143535-10-7 tert-butyl 1-(4-chlorophenyl)-2-(chlorosulfonyl)ethylcarbamate 
• 1143535-12-9 tert-butyl 1-(4-chlorophenyl)-2-sulfamoylethylcarbamate 
• 1143535-14-1 2-amino-2-(4-chlorophenyl)ethanesulfonamide 
• 1082584-93-7 tert-butyl 2-amino-1-(4-chlorophenyl)ethylcarbamate 
• 1143535-18-5 tert-butyl 2-acetamido-1-(4-chlorophenyl)ethylcarbamate 
• 1143535-20-9 N-[2-amino-2-(4-chlorophenyl)ethyl]acetamide 
• 1143535-02-7 tert-butyl 1-(4-chlorophenyl)-2-(methylsulfonamido)ethylcarbamate 
• 1143535-04-9 N-[2-amino-2-(4-chlorophenyl)ethyl]methanesulfonamide 
• 1143534-16-0 3-(N-tert-butoxycarbonylamino)-3-(4'-chlorophenyl)propanitrile 
• 885595-59-5 tert-butyl 3-amino-1-(4-chlorophenyl)propylcarbamate 
• 1143535-82-3 tert-butyl 1-(4-chlorophenyl)-3-(methylsulfonamido)propylcarbamate 
• 1143535-84-5 N-[3-amino-3-(4-chlorophenyl)propyl]methanesulfonamide 

Relevant academic research and scientific papers

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases

Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.

PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising th

PYRROLO [2,3-D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS

The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I)